Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGT-181 in MPS I (Hurler Syndrome)
NCT03053089Phase 2Completed
- Sponsor
- ArmaGen
- Start
- Oct 2015
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of valanafusp alpha in mucopolysaccharidosis type I, sponsored by ArmaGen. Started Oct 2015; status: completed.
02
Drugs
valanafusp alpha
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT03053089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053089.